Human RGM-A Antibody

R&D Systems | Catalog # AF2459

R&D Systems

Key Product Details

Species Reactivity

Validated:

Human

Cited:

Human, Mouse

Applications

Validated:

Immunohistochemistry, Western Blot

Cited:

Immunohistochemistry, Western Blot, Flow Cytometry

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
Loading...

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human RGM-A
Cys48-Gly422
Accession # Q96B86

Specificity

Detects human RGM-A in direct ELISAs and Western blots.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human RGM-A Antibody

RGM-A antibody in Human Brain by Immunohistochemistry (IHC-P).

RGM‑A in Human Brain.

RGM-A was detected in immersion fixed paraffin-embedded sections of human brain (spinal cord) using Goat Anti-Human RGM-A Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2459) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to the dorsal horn. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.
Detection of RGM-A by Western Blot

Detection of RGM-A by Western Blot

HFE2 administration significantly improves EAE disease outcome. A Western Blot analysis shows a strong HFE2 reduction in EAE animal serum when compared to control. ELISA quantification showing HFE2 decrease and RGMa increase in EAE animal serum (mean ± s.d.; EAE n = 3 and RGMa n = 3). b Body conditioning assessment (‘0’ no paralysis to ‘4’ forelimb weakness) of EAE-induced mice with HFE2 + /- RGMa treatment every 3 days (d3, 6, 9, 12 and 15; mean ± s.e.m.; unpaired two-tail t-tests; PBS n = 8, HFE2 n = 6, RGMa+ HFE2 n = 8). c Body conditioning assessment of EAE-induced Hfe2fl/fl and Hfe2 delta Alb-cre mice (mean ± s.e.m.; unpaired two-tail t-tests; Hfe2fl/fln = 8 and Hfe2 delta Alb-cren = 8). d Representative confocal images of CD3 +, B220+ and CD11b+ immune staining in spinal cord of EAE-induced mice 3 weeks after induction and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 7, HFE2 n = 6 mice; technical replicates shown). e Schematic of activated immune cell adoptive transfer. Representative confocal images of CD4-positive labelled transferred cell (CellVue) in PBS-treated or HFE2-treated recipient WT mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 6, HFE2 n = 6). Ptx; Pertussis Toxin. f Representative confocal images of fibrinogen in the spinal cord of HFE2-treated EAE-mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS-treated n = 6 and HFE2 n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://www.nature.com/articles/s41467-024-45303-1), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Flow Cytometry

Detection of RGM-A by Flow Cytometry

RGMA gene induction is HTLV-1 Tax dependent.(A) Tax (left), HBZ (middle), and RGMA (right) gene expression levels in cultured HAM-PBMCs (n = 7) in a time-dependent manner. RPL19 was used as an internal control. (B) Tax-dependent RGMA mRNA gene induction in Jurkat cells, which were infected with lentivirus carrying the Tax gene. Top: Tax expression in the Jurkat cells was confirmed by Western blotting. beta -Actin was measured as an internal control. Bottom: The induction levels of the RGMA gene were evaluated by qRT-PCR in a time-dependent manner (n = 3). (C) Tax-dependent RGMA mRNA gene induction in JPX9 cells treated with 20 μM CdCl2 in a time-dependent manner. Tax mRNA (upper) and RGMA mRNA (bottom) were measured by qRT-PCR (n = 3). GAPDH was measured as an internal control. (D) Tax-dependent RGMa protein induction in JPX9 cells treated with 20 μM CdCl2 for 3 days. Dot plots of Tax and normal goat IgG (upper) or RGMa expression (bottom) in JPX9 cells. JPX9(-), untreated JPX9 cells; 20 μM CdCl2 JPX9, CdCl2-supplemented JPX9 cells. Data are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-way ANOVA with Dunnett’s multiple-comparison test (A), 2-sided Student’s t test (B), or an unpaired t test (C). Experiments were performed in triplicate (B and C). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40305434), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Immunohistochemistry

Detection of RGM-A by Immunohistochemistry

Soluble HFE2 and RGMa effects on endothelial cells.a Knockout of liver Hfe2 reduces pericyte coverage in section from the cerebral cortex (mean ± s.e.m.; unpaired two-tail t-test; AAV8-GFP n = 3, Hfe2 delta Alb-cren = 4, and AAV8-AlbCre n = 3). Scale bar, 50μm. b Quantification through quantitative RT-PCR shows a reduction in PDGF-B mRNA levels in liver knock out animals (mean ± s.e.m.; paired two-tail t-test; Hfe2fl/fln = 3 and Hfe2 delta Alb-cren = 3). c Quantification of PDGF-B mRNA in cultured bEnd.3 cells following indicated treatments. Treatment with RGMa leads to a significant reduction of PDGF-B mRNA levels that is rescued with HFE2 addition (mean ± s.e.m.; paired two-tail t-test; HFE2 n = 3, RGMa n = 4, and RGMa+ HFE2 n = 5; n representing an independent experiment). d Immunocytochemistry of claudin-5 in human primary endothelial cell monolayer after PBS, HFE2, RGMa, and RGMa+HFE2 treatments and quantification (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). Scale bar, 100 µm. e Western blotting of Claudin-5 expression in bEnd3 cell lysates after indicated treatment (mean ± s.e.m.; unpaired two-tailed t-test; replicates n = 3). f Transwell permeability leakage assay performed on a monolayer of bEnd3 cells using HRP (mean ± s.e.m.; paired one-tail t-test; replicates n = 3). g Transwell permeability leakage assay performed on a monolayer of human primary endothelial cells using 70 kDa FITC-dextran (mean ± s.e.m.; paired two-tail t-test; replicates n = 3). h In vitro TEER analysis shows that RGMa alters the integrity of a monolayer of bEnd3 cells, this is rescued by HFE2 (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Immunohistochemistry

Detection of RGM-A by Immunohistochemistry

HFE2 and RGMa have opposite effects on BCB integrity.a 3D rendered representative light-sheet microscopic images of RGMa and RGMa+ HFE2 treated brains (scale bar, 400 µm) and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 3, RGMa n = 5, RGMa+Hfe2 n = 4). b Representative in-vivo multiphoton images from the cerebral cortex of RGMa and RGMa+ HFE2 treated animals. The normalized extravascular fluorescence ( delta F/F) intensity was plotted over time (mean ± s.e.m.; unpaired two-tail t-tests) and the group differences were assessed with spatial leakage log-likelihood (repeated measures factorial ANOVA rendered as approximate unpaired two-tail t-test; PBS n = 6, RGMa n = 5, RGMa+ HFE2 n = 7). c Representative confocal images of fibrinogen disposition around the vessels of the cerebral cortex (isolectin) of RGMa and RGMa+ HFE2 treated mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 5, RGMa n = 5, RGMa+ HFE2 n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Western Blot

Detection of RGM-A by Western Blot

RGMA gene induction is HTLV-1 Tax dependent.(A) Tax (left), HBZ (middle), and RGMA (right) gene expression levels in cultured HAM-PBMCs (n = 7) in a time-dependent manner. RPL19 was used as an internal control. (B) Tax-dependent RGMA mRNA gene induction in Jurkat cells, which were infected with lentivirus carrying the Tax gene. Top: Tax expression in the Jurkat cells was confirmed by Western blotting. beta -Actin was measured as an internal control. Bottom: The induction levels of the RGMA gene were evaluated by qRT-PCR in a time-dependent manner (n = 3). (C) Tax-dependent RGMA mRNA gene induction in JPX9 cells treated with 20 μM CdCl2 in a time-dependent manner. Tax mRNA (upper) and RGMA mRNA (bottom) were measured by qRT-PCR (n = 3). GAPDH was measured as an internal control. (D) Tax-dependent RGMa protein induction in JPX9 cells treated with 20 μM CdCl2 for 3 days. Dot plots of Tax and normal goat IgG (upper) or RGMa expression (bottom) in JPX9 cells. JPX9(-), untreated JPX9 cells; 20 μM CdCl2 JPX9, CdCl2-supplemented JPX9 cells. Data are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-way ANOVA with Dunnett’s multiple-comparison test (A), 2-sided Student’s t test (B), or an unpaired t test (C). Experiments were performed in triplicate (B and C). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40305434), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Flow Cytometry

Detection of RGM-A by Flow Cytometry

RGMA gene induction is HTLV-1 Tax dependent.(A) Tax (left), HBZ (middle), and RGMA (right) gene expression levels in cultured HAM-PBMCs (n = 7) in a time-dependent manner. RPL19 was used as an internal control. (B) Tax-dependent RGMA mRNA gene induction in Jurkat cells, which were infected with lentivirus carrying the Tax gene. Top: Tax expression in the Jurkat cells was confirmed by Western blotting. beta -Actin was measured as an internal control. Bottom: The induction levels of the RGMA gene were evaluated by qRT-PCR in a time-dependent manner (n = 3). (C) Tax-dependent RGMA mRNA gene induction in JPX9 cells treated with 20 μM CdCl2 in a time-dependent manner. Tax mRNA (upper) and RGMA mRNA (bottom) were measured by qRT-PCR (n = 3). GAPDH was measured as an internal control. (D) Tax-dependent RGMa protein induction in JPX9 cells treated with 20 μM CdCl2 for 3 days. Dot plots of Tax and normal goat IgG (upper) or RGMa expression (bottom) in JPX9 cells. JPX9(-), untreated JPX9 cells; 20 μM CdCl2 JPX9, CdCl2-supplemented JPX9 cells. Data are shown as mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001 by 1-way ANOVA with Dunnett’s multiple-comparison test (A), 2-sided Student’s t test (B), or an unpaired t test (C). Experiments were performed in triplicate (B and C). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40305434), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Western Blot

Detection of RGM-A by Western Blot

Soluble HFE2 and RGMa effects on endothelial cells.a Knockout of liver Hfe2 reduces pericyte coverage in section from the cerebral cortex (mean ± s.e.m.; unpaired two-tail t-test; AAV8-GFP n = 3, Hfe2 delta Alb-cren = 4, and AAV8-AlbCre n = 3). Scale bar, 50μm. b Quantification through quantitative RT-PCR shows a reduction in PDGF-B mRNA levels in liver knock out animals (mean ± s.e.m.; paired two-tail t-test; Hfe2fl/fln = 3 and Hfe2 delta Alb-cren = 3). c Quantification of PDGF-B mRNA in cultured bEnd.3 cells following indicated treatments. Treatment with RGMa leads to a significant reduction of PDGF-B mRNA levels that is rescued with HFE2 addition (mean ± s.e.m.; paired two-tail t-test; HFE2 n = 3, RGMa n = 4, and RGMa+ HFE2 n = 5; n representing an independent experiment). d Immunocytochemistry of claudin-5 in human primary endothelial cell monolayer after PBS, HFE2, RGMa, and RGMa+HFE2 treatments and quantification (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). Scale bar, 100 µm. e Western blotting of Claudin-5 expression in bEnd3 cell lysates after indicated treatment (mean ± s.e.m.; unpaired two-tailed t-test; replicates n = 3). f Transwell permeability leakage assay performed on a monolayer of bEnd3 cells using HRP (mean ± s.e.m.; paired one-tail t-test; replicates n = 3). g Transwell permeability leakage assay performed on a monolayer of human primary endothelial cells using 70 kDa FITC-dextran (mean ± s.e.m.; paired two-tail t-test; replicates n = 3). h In vitro TEER analysis shows that RGMa alters the integrity of a monolayer of bEnd3 cells, this is rescued by HFE2 (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-A by Western Blot

Detection of RGM-A by Western Blot

HFE2 administration significantly improves EAE disease outcome.a Western Blot analysis shows a strong HFE2 reduction in EAE animal serum when compared to control. ELISA quantification showing HFE2 decrease and RGMa increase in EAE animal serum (mean ± s.d.; EAE n = 3 and RGMa n = 3). b Body conditioning assessment (‘0’ no paralysis to ‘4’ forelimb weakness) of EAE-induced mice with HFE2 + /- RGMa treatment every 3 days (d3, 6, 9, 12 and 15; mean ± s.e.m.; unpaired two-tail t-tests; PBS n = 8, HFE2 n = 6, RGMa+ HFE2 n = 8). c Body conditioning assessment of EAE-induced Hfe2fl/fl and Hfe2 delta Alb-cre mice (mean ± s.e.m.; unpaired two-tail t-tests; Hfe2fl/fln = 8 and Hfe2 delta Alb-cren = 8). d Representative confocal images of CD3 +, B220+ and CD11b+ immune staining in spinal cord of EAE-induced mice 3 weeks after induction and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 7, HFE2 n = 6 mice; technical replicates shown). e Schematic of activated immune cell adoptive transfer. Representative confocal images of CD4-positive labelled transferred cell (CellVue) in PBS-treated or HFE2-treated recipient WT mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 6, HFE2 n = 6). Ptx; Pertussis Toxin. f Representative confocal images of fibrinogen in the spinal cord of HFE2-treated EAE-mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS-treated n = 6 and HFE2 n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human RGM-A Antibody

Application
Recommended Usage

Immunohistochemistry

10-25 µg/mL
Sample: Formalin fixed paraffin-embedded sections of human spinal cord subjected to Antigen Retrieval Reagent-Basic (Catalog # CTS013)

Western Blot

0.1 µg/mL
Sample: Recombinant Human Repulsive Guidance Molecule A/RGM-A (Catalog # 2459-RM)

Reviewed Applications

Read 1 review rated 5 using AF2459 in the following applications:

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.


Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: RGM-A

Human Repulsive Guidance molecule (RGM) is a 33 kDa GPI-linked member of an expanding RGM-related family of neuronal and muscle-expressed membrane proteins (1). It is synthesized as a 450 amino acid (aa) preproprotein that contains a 47 aa signal sequence, a 121 aa N-terminal prosegment, a 256 mature region and a 26 aa C-terminal prosegment (2). The N-terminal prosegment contains an RGD tripeptide and the molecule’s only two potential N-linked glycosylation sites. The mature segment shows an abbreviated von Willebrand factor domain. Proteolytic processing occurs at an aspartic acid-proline bond, creating a predicted 32 kDa mature region (2). The mature region of human RGM-A has 88% and 93% aa identity to the chick and mouse mature region of RGM-A, respectively. When compared to human RGMb and c, the mature region of human RGM-A shows 58% and 54% aa identity, respectively. Recombinant chick RGM-A has been reported to induce collapse of temporal but not nasal growth cones, and to repel temporal retinal axons in vitro. This suggests a role in the development of the retina-superior colliculus connection. In mammals, however, this activity is not so evident, and thus its function in this system is uncertain (3). Alternatively, in mice, RGM-A is said to be needed for neural tube closure, and may play a role in entorhinal-hippocampal connections (3, 4). The receptor for RGM-A is reported to be neogenin (5, 6). RGM-A has also been shown to be a bone morphogenic protein co-receptor, able to bind both BMP-2 and BMP-4 (7).

References

  1. Samad, T.A. et al. (2004) J. Neurosci. 24:2027.
  2. Monnier P. et al. (2002) Nature 419:392.
  3. Niederkofler V. et al. (2004) J. Neurosci. 24:808.
  4. Brinks, H. et al. (2004) J. Neurosci. 24:3862.
  5. Rajagopalan S. et al. (2004) Nat. Cell Biol. 6:756.
  6. Matsunaga E. et al. (2004) Nat. Cell Biol. 6:749.
  7. Babitt J.L. et al. (2005) J. Biol. Chem. 280(33):29820.

Long Name

Repulsive Guidance Molecule A

Alternate Names

RGMA

Entrez Gene IDs

56963 (Human); 244058 (Mouse)

Gene Symbol

RGMA

UniProt

Additional RGM-A Products

Product Documents for Human RGM-A Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.


Can't find your language? Request a SDS in your language here.

Product Specific Notices for Human RGM-A Antibody

For research use only

Related Research Areas

Citations for Human RGM-A Antibody

Customer Reviews for Human RGM-A Antibody (1)

5 out of 5
1 Customer Rating
5 Stars
100%
4 Stars
0%
3 Stars
0%
2 Stars
0%
1 Stars
0%

Have you used Human RGM-A Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Customer Images


Showing  1 - 1 of 1 review Showing All
Filter By:
  • Human RGM-A Antibody
    Name: Anonymous
    Application: Functional Assay
    Sample Tested: Recombinant protein
    Species: Human
    Verified Customer | Posted 02/04/2025
    Worked in detecting 2459-RM in in vitro assay
    Human RGM-A Antibody AF2459

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies
Loading...